IP Library Granted Patent US 10,471,125
Granted Patent B2
US 10,471,125 · App. 15/118,337 · Granted Nov 12, 2019

Pharmaceutical compositions and their use for the treatment of autoimmune disorders

Inventors: Bertrand Huard (Grenoble, FR); Patrice Lalive (Chene-Bougeries, CH)
Assignee: UNIVERSITE GRENOBLE ALPES
A61K38/191A61K9/0019A61K38/395C07K14/47C07K14/525C07K2319/20C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,471,125
App. No.
15/118,337
Granted
Nov 12, 2019
Kind
B2
Abstract

A pharmaceutical composition in which the active substance includes or is: (i) a protein including the sequence SEQ ID NO: 1, representing the APRIL protein, (ii) any derived protein, which is derived from protein of sequence SEQ ID NO: 1 by substitution, removal or addition of one or more amino-acids, provided it allows the binding of the derived protein to an astrocyte and/or CSPG, (iii) any homologous protein, the sequence of which has a percentage of identity of at least approximately 70%, and in particular 85% with the sequence SEQ ID NO: 1, provided it allows the binding of the homologous protein to an astrocyte and/or CSPG, or (iv) any fragment of the protein of sequence SEQ ID NO: 1, provided it allows the binding of the fragment to an astrocyte and/or CSPG. The active substance is in association with an acceptable pharmaceutical vehicle.

Claims (10)

1. A method of interfering with an antiregenerative process mediated by Chondroitin Sulfate ProteoGlycans (CSPG) comprising administering to a subject in need thereof a composition comprising an active substance which comprises or consists of:

a protein comprising one of the amino acid sequences of SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO:3, representing the APRIL protein.

2. The method according to claim 1 , wherein the protein of the composition is a chimeric protein consisting of an oligomer of the protein of one of the amino acid sequences of SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO:3, each protein of the oligomer being linked to another protein of the oligomer by a constant region of an immunoglobulin of an amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10.

3. The method according to claim 1 , wherein the protein of the composition is a chimeric protein consisting of an oligomer of the protein of one of the amino acid sequences of SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO:3, each protein of the oligomer being linked to the headless region of an ACRP30 protein of an amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 8.

4. The method according to claim 1 , wherein the active substance of the composition forms a complex with an astrocyte and/or to CSPG, the active substance being:

(i) the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3, or

(ii) a chimeric protein consisting of an oligomer of the protein of one of the amino acid sequences of SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO:3, each protein of the oligomer being linked to another protein of the oligomer by a constant region of an immunoglobulin of an amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10, or

(iii) a chimeric protein consisting of an oligomer of the protein of one of the amino acid sequences of SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO:3, each protein of the oligomer being linked to the headless region of an ACRP30 protein of an amino acid sequence of SEQ ID NO: 7 or SEQ ID NO: 8.

5. A method for treating multiple sclerosis or autoimmune encephalitis, said method comprising administering to a subject in need thereof an effective amount of a composition comprising an active substance which comprises or consists of:

a protein comprising one of the amino acid sequences of SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO:3, representing the APRIL protein.

Assignments (3)
MERGER Recorded Jun 29, 2022
From: UNIVERSITÉ GRENOBLE ALPES (SIREN NO. 130 021 397)
To: UNIVERSITÉ GRENOBLE ALPES (SIREN NO. 130 026 081)
Reel/Frame 060528/0718 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S NAME PREVIOUSLY RECORDED AT REEL: 040460 FRAME: 0359. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Oct 1, 2019
From: HUARD, BERTRAND; LALIVE, PATRICE
To: UNIVERSITE GRENOBLE ALPES
Reel/Frame 050598/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2016
From: HUARD, BERTRAND; LALIVE, PATRICE
To: UNIVERISTE GRENOBLE ALPES
Reel/Frame 040460/0359 →
Priority Claims (1)
EP 14305362 · Mar 13, 2014 · regional
Continuity (1)
Related Publication 20170128536A1 · May 11, 2017